Skip to main content

Prevalence of Cirrhosis Higher for Trans- Versus Cisgender Adults

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 26, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Dec. 26, 2024 -- Trans- versus cisgender adults have an increased prevalence of cirrhosis but similar five-year survival, according to a study published in the December issue of the American Journal of Gastroenterology.

Hirsh Elhence, from the Keck School of Medicine at the University of Southern California in Los Angeles, and colleagues calculated the age-standardized prevalence of cirrhosis among cisgender versus transgender adults in the Optum deidentified Clinformatics Data Mart Database between 2007 and 2022. For those with diagnoses of incident cirrhosis, age-standardized incidence densities of liver-related outcomes and all-cause mortality were calculated. Using inverse probability treatment weighting, five-year survival was examined.

Overall, 0.07 percent of the 64,615,316 adults were transgender; 0.09 percent of the 329,251 adults with cirrhosis were transgender. The researchers found that the prevalence of cirrhosis was higher for trans- versus cisgender adults (1,285 versus 561 per 100,000). Among those with cirrhosis, trans- versus cisgender adults had higher proportions of anxiety (70.7 versus 43.2 percent), depression (66.4 versus 38.4 percent), HIV/AIDS (8.5 versus 1.6 percent), and alcohol (57.5 versus 51.0 percent) and viral etiologies (30.5 versus 24.2 percent). Similar densities of death, decompensation, and liver transplantation were seen for trans- versus cisgender adults (12.0 versus 14.0, 15.7 versus 14.1, and 0.3 versus 0.3 per 100 person-years, respectively). Transgender and cisgender individuals were found to have similar five-year survival probabilities in an inverse probability treatment weighting survival analysis (63.4 versus 59.1 percent).

"Our findings suggest that transgender individuals represent a vulnerable population that require specific attention from clinicians and researchers alike," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted December 2024

Read this next

Testosterone Use Not Tied to Gynecological Cancers in Transmasculine Individuals

FRIDAY, May 16, 2025 -- Short-term testosterone use among transmasculine and gender diverse (TMGD) individuals is not associated with an increased risk for gynecological cancers...

General Practitioners Face Barriers to Treating Patients' Sexual Problems

MONDAY, May 12, 2025 -- While treating sexual problems is considered an important health care practice, general practitioners (GPs) report more barriers to caring for...

Gender-Affirming Hormone Therapy in Primary Care Tied to Reduced Depressive Symptoms

MONDAY, March 24, 2025 -- Gender-affirming hormone therapy (GAHT) in primary care is associated with lower rates of moderate-to-severe depressive symptoms in U.S. transgender...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.